Other hypotheses have been proposed, including that the use of PD-1 inhibitors may lead to a pro-inflammatory cascade involving T-lymphocytes, interleukins (IL-2, IL-6, IL-17) and tumor necrosis factor-alpha, which may contribute to the development of MG. Here, IL2 is linked to myasthenia gravis.